Announced
Completed
Financials
Sources
Tags
Acquisition
Private
Completed
Domestic
Private Equity
Venture Capital
Minority
biotechnology company
Biotechnology
Friendly
Single Bidder
United States
Synopsis
Sofinnova Investments, a healthcare investment firm, led a $170m round in BioAge, a clinical-stage biotechnology company, with participation from Longitude Capital, RA Capital, Cormorant Asset Management, RTW Investments, SV Health Investors, OrbiMed Advisors, Sands Capital, Pivotal bioVenture Partners, Osage University Partners, Lilly Ventures, Andreessen Horowitz and Amgen Ventures. “We’re thrilled to partner with a top-tier syndicate of investors and pharma companies at the forefront of developing novel therapeutics for metabolic diseases. This funding will support us through key clinical milestones and data readouts for our lead compound azelaprag in obesity, as well as advance our earlier-stage metabolic aging pipeline. The azelaprag program highlights our discovery platform’s ability to identify novel approaches to treating metabolic disease,” Kristen Fortney, BioAge CEO and Co-Founder.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.